ESMO 2018 Congress

Oncology Meeting Resources

19 Oct - 23 Oct 2018, Munich, Germany

ESMO 2018

Securing access to optimal cancer care!

Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access. Congress attendees should access via the ESMO Conferences platform .
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Meeting programmeFuture ESMO meetings

> ESMO Videos:  Highlights series   |  Expert Report series

Special Sessions and Tracks

More Resources





Format available

https://oncologypro.esmo.org/Meeting-Resour...ality-treatment-of-leptomeningeal-metastasis

Date: 19 Oct 2018
Presenter: Emilie Le Rhun
Resources: Presentation
Topics: Central Nervous System Malignancies, Therapy

https://oncologypro.esmo.org/Meeting-Resour...zed-prostate-cancer-with-a-12-year-follow-up

BackgroundGETUG-12 assessed docetaxel-estramustine in patients with high-risk localized prostate cancer: the primary endpoint of relapse-free survival (RFS) was met (adjusted HR: 0.71 [95% CI: 0.54-0.

Date: 19 Oct 2018
Presenter: Karim Fizazi
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Prostate Cancer

https://oncologypro.esmo.org/Meeting-Resour...ary-tumours-prostate-Invited-Discussant-791O

Date: 19 Oct 2018
Presenter: Eleni Efstathiou
Resources: Presentation, Webcast
Topic: Prostate Cancer

https://oncologypro.esmo.org/Meeting-Resour...bone-predominant-metastatic-castration-resis

BackgroundAbiraterone acetate and prednisone/prednisolone (AAP) improves progression-free survival and overall survival (OS) in men with mCRPC. Ra-223 increases OS and decreases symptomatic skeletal...

Date: 19 Oct 2018
Presenter: Matthew Smith
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Prostate Cancer, Radiation Oncology

https://oncologypro.esmo.org/Meeting-Resour...ry-tumours-prostate-Invited-Discussant-LBA30

Date: 19 Oct 2018
Presenter: Daniel Heinrich
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...c-Castration-Resistant-Prostate-Cancer-mCRPC

BackgroundThe optimal treatment for poor prognosis mCRPC is undefined and includes either taxane chemotherapy or androgen receptor (AR) targeted therapy, emphasizing the need for predictive biomarkers...

Date: 19 Oct 2018
Presenter: Kim Chi
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Prostate Cancer

https://oncologypro.esmo.org/Meeting-Resour...ary-tumours-prostate-Invited-Discussant-792O

Date: 19 Oct 2018
Presenter: Stéphane Oudard
Resources: Presentation, Webcast
Topic: Prostate Cancer

https://oncologypro.esmo.org/Meeting-Resour...rian-cancer-patients-Results-of-CORAIL-trial

BackgroundLurbinectedin (L) is a new anticancer agent that blocks transcriptional transactivation, induces DNA double-strand breaks, and modulates the tumor microenvironment.

Date: 19 Oct 2018
Presenter: Stephanie Gaillard
Resources: Abstract, Presentation, Webcast
Topics: Ovarian Cancer, Anticancer Agents

https://oncologypro.esmo.org/Meeting-Resour...group-study-AGO-Study-Group-AGO-Austria-ANZG

BackgroundIn patients with recurrent ovarian cancer (ROC) suitable for platinum-based retreatment (PBT), standard includes CG-BEV and Carboplatin(C)/pegylated-liposomal- Doxorubicin (D).

Date: 19 Oct 2018
Presenter: Jacobus Pfisterer
Resources: Abstract, Presentation, Webcast
Topics: Ovarian Cancer, Anticancer Agents

https://oncologypro.esmo.org/Meeting-Resour...cers-Invited-Discussant-One-LBA-TBC-and-932O

Date: 19 Oct 2018
Presenter: Sandro Pignata
Resources: Presentation, Webcast